[go: up one dir, main page]

AU2001265714A1 - Marker for neurodegenerative diseases and its use for drug screening targeted against said diseases - Google Patents

Marker for neurodegenerative diseases and its use for drug screening targeted against said diseases

Info

Publication number
AU2001265714A1
AU2001265714A1 AU2001265714A AU6571401A AU2001265714A1 AU 2001265714 A1 AU2001265714 A1 AU 2001265714A1 AU 2001265714 A AU2001265714 A AU 2001265714A AU 6571401 A AU6571401 A AU 6571401A AU 2001265714 A1 AU2001265714 A1 AU 2001265714A1
Authority
AU
Australia
Prior art keywords
diseases
marker
drug screening
targeted against
screening targeted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001265714A
Inventor
Claus Heizmann
Bernhard Keller
Roland Pochet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Libre de Bruxelles ULB
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Universite Libre de Bruxelles ULB
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Libre de Bruxelles ULB, Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Universite Libre de Bruxelles ULB
Publication of AU2001265714A1 publication Critical patent/AU2001265714A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4727Calcium binding proteins, e.g. calmodulin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001265714A 2000-06-14 2001-06-14 Marker for neurodegenerative diseases and its use for drug screening targeted against said diseases Abandoned AU2001265714A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21141200P 2000-06-14 2000-06-14
US60211412 2000-06-14
PCT/BE2001/000100 WO2001096878A2 (en) 2000-06-14 2001-06-14 Marker for neurodegerative diseases and its use in drug screening

Publications (1)

Publication Number Publication Date
AU2001265714A1 true AU2001265714A1 (en) 2001-12-24

Family

ID=22786822

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001265714A Abandoned AU2001265714A1 (en) 2000-06-14 2001-06-14 Marker for neurodegenerative diseases and its use for drug screening targeted against said diseases

Country Status (2)

Country Link
AU (1) AU2001265714A1 (en)
WO (1) WO2001096878A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109862A2 (en) * 2008-03-06 2009-09-11 Rolf Lewensohn Improved cancer therapeutics
EP2418491A1 (en) * 2010-08-10 2012-02-15 Bioftalmik, S.L. Method for the diagnosis of dry eye and blepharitis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602677D0 (en) * 1996-07-05 1996-07-05 Sangtec Medical Ab Methods for determining brain antigens
DE19707230C2 (en) * 1997-02-24 2000-01-13 Markus Otto Method for recognizing a disease of an organism from transmissible spongiform encephalopathy

Also Published As

Publication number Publication date
WO2001096878A2 (en) 2001-12-20
WO2001096878A3 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
AU2002213357A1 (en) Variant igg3 rituxan r and therapeutic use thereof
AU2001269529A1 (en) Medicine comprising dicyanopyridine derivative
IL139975A0 (en) Anti proliferative drugs
AU7815000A (en) Targeted drug activation
AU2001253020A1 (en) Screening markers and methods for neurodegenerative disorders
AU2003235956A1 (en) Quinazoline derivative and medicine
AU2001271841A1 (en) Methods for identifying combinations of drugs
AU2002248213A1 (en) Markers for disease susceptibility and targets for therapy
AU2002221099A1 (en) Combination drugs
AU2001286721A1 (en) Human interleukin-four induced protein
AU2001227084A1 (en) N-arylhydrazide compounds and use thereof as drugs
AU2001241162A1 (en) Remedies for allergic diseases
AU2003217782A1 (en) Dna-binding polyamide drug conjugates
AU2001232244A1 (en) Drug comprising combination
AU2002241758A1 (en) Drug screening system
AU2001291691A1 (en) Drugs for incontinence
AU2001280133A1 (en) Preventives and remedies for central nervous system diseases
EP1325751A4 (en) Novel drugs for liver diseases
AU2001265714A1 (en) Marker for neurodegenerative diseases and its use for drug screening targeted against said diseases
AU2001262741A1 (en) Medicines for the prevention and treatment of neurodegenerative diseases
AUPR548601A0 (en) Pyrazolopyrazinecompound and pharmaceutical use thereof
AU2001262952A1 (en) Fullerene-based drugs targeted to bone
AU2002249453A1 (en) Enzyme and snp marker for disease
AU2001228784A1 (en) Inositol derivatives and their pharmaceutical use
AU2002322247A1 (en) Antibacterial oxazinones and methods for their use and synthesis